Primary Category:
Treatment Protocols
Disease Category:
Endometrial, Gynecologic
Status:
Upcoming - Pending IRB Review
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVB or Recurrent Endometrial Cancer
NCT#03914612
